Development of new-generation gene-therapy immuno-therapy for alzheimer's disease

Abstract

It is possible to realize gene therapy with immunotherapy for Alzheimer's disease with a sustaining effect compared to antibody investment and a higher antibody capacity compared to a single chain antibody. An integrated anti-[beta]-amyloid antibody or a fragmented carrier is expressed, where the carrier contains a promoter sequence, a coding sequence of an immunoglobulin heavy chain or its fragment of anti-[beta]-amyloid antibody, for coding a self-processing peptide sequence and coding a sequence of an immunoglobulin heavy chain of anti-[beta]-amyloid antibody. Prevention of Alzheimer's disease with the carrier as an active ingredient and therapeutic medication are included.

Description

technical field [0001] The present invention relates to a carrier introduced with an anti-β-amyloid antibody gene or an improved version thereof, which can be used in gene therapy and immunotherapy for Alzheimer's disease. Background technique [0002] The main pathological features of human Alzheimer's disease (AD) are senile plaques and changes in nerve fibers, and once they progress further, reduction of nerve cells and brain atrophy can be observed. It is well known that senile plaques are caused by the accumulation of β-amyloid (Aβ) cleaved from the receptor amyloid precursor protein (APP) on the cell membrane. In addition, in recent years, neurotoxicity of not only insoluble Aβ but also soluble Aβ aggregates has been confirmed, attracting great attention (Non-Patent Document 1). One AD drug approved in Japan is just a precursor to a cholinesterase inhibitor, which compensates for lost nerve transmission and only suppresses symptoms, not cures. [0003] Therefore, in ...

AI Technical Summary

Problems solved by technology

However, in general, the antibody capacity of light chain antibodies is lower than that of intact antibodies

Images